Delayed acute pancreatitis induced by nilotinib in a patient with chronic myeloid leukemia attaining sustained complete molecular response

Advent of tyrosine kinase inhibitors (TKI) have revolutionized therapy of chronic myeloid leukemia. Imatinib was the first agent utilized in the therapy of CML. Nilotinib, a second generation TKI, results in an increase in number of patients achieving major molecular response at an earlier time poin...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Shifang, Desikan, Sai Prasad, Jeffrey, Jay, McClain, Charles, Desikan, Raman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175719/
https://www.ncbi.nlm.nih.gov/pubmed/35847739
http://dx.doi.org/10.1002/jha2.21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175719/
https://www.ncbi.nlm.nih.gov/pubmed/35847739
http://dx.doi.org/10.1002/jha2.21

Ejemplares similares